Testing effectiveness (Phase 2)Active Not RecruitingNCT01089101
What this trial is testing
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Who this might be right for
Low Grade GliomaRecurrent Childhood Pilocytic AstrocytomaRecurrent Neurofibromatosis Type 1+3 more
National Cancer Institute (NCI) 217